Protara Therapeutics (TARA) Change in Accured Expenses (2013 - 2026)

Protara Therapeutics' Change in Accured Expenses history runs 14 years deep, the most recent figure standing at -$2.6 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 39.14% year-over-year to -$2.6 million; the TTM figure through Mar 2026 stood at $89000.0 (up 888.89% YoY), while the FY2025 annual figure was $821000.0, down 69.32% from the prior year.
• Change in Accured Expenses was -$2.6 million for Q1 2026 at Protara Therapeutics, down from $2.0 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $2.0 million in Q4 2025 to a low of -$2.6 million in Q1 2026.
• Historically, Change in Accured Expenses has averaged -$55117.6 across 5 years, with a median of $140000.0 in 2024.
• Biggest YoY gain for Change in Accured Expenses was 1360.0% in 2025; the steepest drop was 334.63% in 2025.
• A 5-year view of Change in Accured Expenses shows it stood at -$1.2 million in 2022, then jumped by 51.93% to -$573000.0 in 2023, then soared by 124.43% to $140000.0 in 2024, then jumped by 1360.0% to $2.0 million in 2025, then slumped by 227.3% to -$2.6 million in 2026.
• The last three Change in Accured Expenses figures came in at -$2.6 million (Q1 2026), $2.0 million (Q4 2025), and $922000.0 (Q3 2025), per Business Quant data.